Authors

Latest:

HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy

Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.

Rolando Ruiz, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Rolf A. Stahel, MD

Latest:

Dr. Stahel on Treatment Sequencing in Stage IV NSCLC

Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.

Roman Perez-Soler, MD

Latest:

Dr. Perez-Soler on the Utility of Liquid Biopsy in Lung Cancer

Roman Perez-Soler, MD, discusses the utility of liquid biopsy in lung cancer.

Ron Bose, MD, PhD

Latest:

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

Ronald B. Natale, MD

Latest:

Dr. Natale on the Evolution of Immunotherapy in NSCLC

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Ronald de Wit, MD, PhD

Latest:

Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ronald Go, MD

Latest:

Dr. Go on Treatment of Patients With Thrombotic Microangiopathy

Ronald Go, MD, associate professor of Medicine, Mayo Clinic, discusses treatment for patients with thrombotic microangiopathy.

Ronald Hoffman, MD

Latest:

Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera

Ronald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.

Ronald J. Scheff, MD, Weill Cornell Medical College

Ronald Natale, MD

Latest:

Dr. Natale on the Evolution of Immunotherapy in NSCLC

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Ronan Flippot, MD, MSc

Latest:

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Ronan J. Kelly, MD, MBA

Latest:

The Future for HER2-Directed ADCs

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Ronan T. Swords, MD, PhD

Latest:

Bringing Epigenetic Therapies From Bench to Bedside

Epigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.

Ronan T. Swords, MD, PhD, FRCPI, FRCPath

Latest:

Dr. Swords on Anti-Tumor Effects of IMG-98 in AML

Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acidâ€“based therapies in acute myeloid leukemia.

Roni Zeiger, MD

Latest:

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.

Rory McCulloch, MD

Latest:

Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCL

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

Rosalyn Juergens, MD, PhD

Latest:

Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Rosandra N. Kaplan, MD

Latest:

Dr. Kaplan on the Treatment of Pediatric Patients With Sarcoma

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with sarcoma.

Rosario Garcia Campelo, MD

Latest:

Dr. Campelo on the Rationale for the ALTA-1L Trial

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.